BELLEVUE, Wash., June 29 /PRNewswire-FirstCall/ -- Ascentia Biomedical Corporation , a leading researcher and developer of efficacious pharmaceuticals, compounds and other products, announces its common stock has begun trading on the OTC Pink Sheets under the ticker symbol ASCE. Pink Sheets LLC provides quotes and other information at http://www.pinksheets.com
Dr. James Clagett, President and CEO of Ascentia said, “We are pleased to have begun trading on the Pink Sheets, but it is just the first step of our goal of being listed on a national exchange. We are excited about the prospects for our research and products. With a growing balance sheet, an experienced management team and a ‘Who’s Who’ for a Scientific Advisory Board, we are well positioned for future growth. We welcome the challenge to build shareholder value by growing our business.”
About Ascentia Biomedical Corporation
Our focus is SOLUTIONS through RESEARCH and DISCOVERY. Ascentia is developing and commercializing new pharmaceutical and biomedical products for application in a number of areas, including treatment for asthma, arthritis, psoriasis and cancer. Initially, a majority of these products will be secured through direct purchase or through licensing. As the Company grows and evolves, more products will be developed internally. Ascentia is focused on therapies for cancer and diseases of inflammation.
For more information visit the Company’s website at: http://www.ascentiabiomedical.com
Certain statements contained herein are “forward looking” statements as such term is defined in the Private Securities Litigation Reform Act of 1995. Because statements include risks and uncertainties, actual results may differ materially from those expressed or implied and include, but are not limited to, those discussed in filings by the Company with the Securities and Exchange Commission.
Ascentia Biomedical Corporation
CONTACT: Dr. James Clagett, President & CEO of Ascentia BiomedicalCorporation, +1-425-462-5686; or Jim Drewitz, Investor Relations,+1-972-355-6070, for Ascentia Biomedical Corporation